Table 1.

Incidence of metastases after intrapancreatic implantation of PC-1.0 (control tumors), PC-1.0/sst2 (sst2 tumors), and a mixed population of PC-1.0/sst2∶PC-1.0 cells (25%∶75%, mixed tumors)

Groups	Metastases on day 13	Metastases on day 20
		− AN-238	+ AN-238
Control	P, 95%; D, 81% (n = 22)	P, 100%; D, 100% (n = 10)	P, 90%; D, 100% (n = 10)
sst2	P, 19%*; D, 19% (n = 26)*	P, 70%*; D, 50% (n = 14)†	P, 36%*‡; D, 36% (n = 14)*
Mixed	P, 43%*; D, 37% (n = 30)*	P, 90%; D, 100% (n = 10)	P, 100%; D, 80% (n = 10)

Results are expressed as percentage of proximal (regional lymph nodes, spleen, stomach, and epiploon) and distal (liver and peritoneum) metastases at 13 and 20 days after implantation, with (+ AN-238) or without (− AN-238) a single i.v. administration of AN-238 analog on day 13. Cumulative results obtained from experiments 1, 2 (day 13; Figs. 2 and 3), and 3 (days 13 and 20; Fig. 3) are given (number of animals evaluated is indicated in parenthesis). P, proximal metastases; D, distal metastases. Difference with control: *, P < 0.001;  

^†, P < 0.05. Difference with untreated animals:  

^‡, P < 0.05 (χ² test).